JP2013518893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518893A5 JP2013518893A5 JP2012552071A JP2012552071A JP2013518893A5 JP 2013518893 A5 JP2013518893 A5 JP 2013518893A5 JP 2012552071 A JP2012552071 A JP 2012552071A JP 2012552071 A JP2012552071 A JP 2012552071A JP 2013518893 A5 JP2013518893 A5 JP 2013518893A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- concentration
- avpal variant
- subject
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 42
- 239000000203 mixture Substances 0.000 claims 42
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 25
- 238000000034 method Methods 0.000 claims 23
- 229960005190 phenylalanine Drugs 0.000 claims 18
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 15
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims 10
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 7
- 201000011252 Phenylketonuria Diseases 0.000 claims 6
- 238000005349 anion exchange Methods 0.000 claims 6
- 239000013592 cell lysate Substances 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 5
- 235000005911 diet Nutrition 0.000 claims 5
- 230000037213 diet Effects 0.000 claims 5
- 210000002381 plasma Anatomy 0.000 claims 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 238000000108 ultra-filtration Methods 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 4
- 230000008014 freezing Effects 0.000 claims 4
- 238000007710 freezing Methods 0.000 claims 4
- 239000006228 supernatant Substances 0.000 claims 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 3
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 238000011026 diafiltration Methods 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 238000010257 thawing Methods 0.000 claims 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 claims 3
- 102220537984 Clavesin-1_S110C_mutation Human genes 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 102200021562 c.1117G>A Human genes 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003599 detergent Substances 0.000 claims 2
- 239000012538 diafiltration buffer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000000265 homogenisation Methods 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 230000002934 lysing effect Effects 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- 102200000387 rs121917857 Human genes 0.000 claims 2
- 102200057376 rs1553135971 Human genes 0.000 claims 2
- 102220034979 rs199475615 Human genes 0.000 claims 2
- 102200027736 rs5030841 Human genes 0.000 claims 2
- 102200031316 rs5030849 Human genes 0.000 claims 2
- 102200031487 rs5030853 Human genes 0.000 claims 2
- 102200031113 rs5030856 Human genes 0.000 claims 2
- 102200031139 rs5030860 Human genes 0.000 claims 2
- 102200031429 rs62514931 Human genes 0.000 claims 2
- 102200031124 rs62516101 Human genes 0.000 claims 2
- 102200031116 rs62516103 Human genes 0.000 claims 2
- 102220034971 rs62642095 Human genes 0.000 claims 2
- 102200027738 rs62642926 Human genes 0.000 claims 2
- 102200027873 rs62642929 Human genes 0.000 claims 2
- 102200031143 rs62644465 Human genes 0.000 claims 2
- 102200027763 rs75193786 Human genes 0.000 claims 2
- 102200027764 rs76394784 Human genes 0.000 claims 2
- 102200031444 rs76687508 Human genes 0.000 claims 2
- 102200031393 rs77958223 Human genes 0.000 claims 2
- 102200094634 rs80356692 Human genes 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30147810P | 2010-02-04 | 2010-02-04 | |
| US61/301,478 | 2010-02-04 | ||
| PCT/US2011/023534 WO2011097335A2 (en) | 2010-02-04 | 2011-02-03 | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518893A JP2013518893A (ja) | 2013-05-23 |
| JP2013518893A5 true JP2013518893A5 (https=) | 2014-03-20 |
| JP5828844B2 JP5828844B2 (ja) | 2015-12-09 |
Family
ID=44356065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552071A Active JP5828844B2 (ja) | 2010-02-04 | 2011-02-03 | 原核生物フェニルアラニンアンモニアリアーゼ変異体の組成物、及び、その組成物を用いる方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20130039898A1 (https=) |
| EP (4) | EP2531209B1 (https=) |
| JP (1) | JP5828844B2 (https=) |
| CN (2) | CN106834261B (https=) |
| AU (1) | AU2011212929B2 (https=) |
| CA (1) | CA2782444C (https=) |
| CY (1) | CY1120768T1 (https=) |
| DK (1) | DK3025728T3 (https=) |
| ES (2) | ES2690542T3 (https=) |
| HK (1) | HK1225299B (https=) |
| HR (1) | HRP20181602T1 (https=) |
| HU (1) | HUE039516T2 (https=) |
| IL (2) | IL221099B (https=) |
| LT (1) | LT3025728T (https=) |
| PL (1) | PL3025728T3 (https=) |
| PT (1) | PT3025728T (https=) |
| SI (1) | SI3025728T1 (https=) |
| WO (1) | WO2011097335A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319601D0 (en) † | 2003-08-20 | 2003-09-24 | Sandoz Ag | Production process |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| ES2690542T3 (es) | 2010-02-04 | 2018-11-21 | Biomarin Pharmaceutical Inc. | Método para purificar variantes de fenilalanina amoníaco-liasa procariotas |
| NZ713396A (en) | 2013-04-18 | 2020-06-26 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| WO2015161019A1 (en) | 2014-04-16 | 2015-10-22 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| TWI743023B (zh) * | 2014-05-21 | 2021-10-21 | 日商Ｋｍ生物醫藥股份有限公司 | 基質金屬蛋白酶 7(mmp-7)聚集體之單體化方法 |
| LT3237621T (lt) | 2014-12-22 | 2023-09-25 | Codexis, Inc. | Žmogaus alfa-galaktozidazės variantai |
| WO2016109899A1 (en) | 2015-01-09 | 2016-07-14 | Mcmaster University | Allosteric activators for treatment of phenylketonuria |
| CN106636048A (zh) * | 2016-12-14 | 2017-05-10 | 江南大学 | 一株酶活提高的苯丙氨酸脱氨酶突变体 |
| MX2019009615A (es) | 2017-02-13 | 2019-10-14 | Codexis Inc | Polipeptidos dise?ados de fenilalanina amonio liasa. |
| CN108424897B (zh) * | 2018-03-13 | 2020-08-14 | 广州铭康生物工程有限公司 | 一种rhTNK-tPA细胞收获液的纯化方法 |
| CN108315338A (zh) * | 2018-04-18 | 2018-07-24 | 山东省果树研究所 | 一种石榴苯丙氨酸解氨酶pal及其表达基因与应用 |
| US10900055B2 (en) | 2018-06-12 | 2021-01-26 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| CA3122524A1 (en) | 2018-12-14 | 2020-06-18 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| AU2019403323B2 (en) | 2018-12-20 | 2026-02-26 | Codexis, Inc. | Human alpha-galactosidase variants |
| EP4501403A3 (en) | 2019-08-30 | 2025-05-14 | Société des Produits Nestlé S.A. | Engineered lipase variants |
| JP2023507575A (ja) | 2019-12-20 | 2023-02-24 | コデクシス， インコーポレイテッド | 操作された酸性アルファ－グルコシダーゼバリアント |
| JP2023512683A (ja) | 2020-02-04 | 2023-03-28 | コデクシス， インコーポレイテッド | 操作されたロイシンデカルボキシラーゼ |
| WO2021168060A1 (en) * | 2020-02-19 | 2021-08-26 | Trustees Of Tufts College | Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained |
| BR112022018571A2 (pt) * | 2020-03-20 | 2022-11-01 | Synlogic Operating Co Inc | Microrganismos manipulados para reduzir a hiperfenilalaninemia |
| CN116897205A (zh) | 2020-08-28 | 2023-10-17 | 科德克希思公司 | 工程化淀粉酶变体 |
| AU2021334371A1 (en) | 2020-08-28 | 2023-03-09 | Codexis, Inc. | Engineered protease variants |
| CN112662606A (zh) * | 2021-01-06 | 2021-04-16 | 中国科学院分子植物科学卓越创新中心 | 用于治疗苯丙酮尿症的工程益生菌 |
| EP4341394A4 (en) | 2021-05-19 | 2025-04-09 | BioMarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients |
| JP2024540358A (ja) | 2021-11-01 | 2024-10-31 | シンティス バイオ，インコーポレイティド | 工学操作ロイシン脱炭酸酵素 |
| WO2024032012A1 (zh) * | 2022-08-10 | 2024-02-15 | 百葵锐(深圳)生物科技有限公司 | 苯丙氨酸解氨酶突变体及其应用 |
| CN116218828A (zh) * | 2022-12-30 | 2023-06-06 | 苏州普瑞森生物科技有限公司 | 一种苯丙氨酸解氨酶、编码基因及其应用 |
| CN118931888A (zh) * | 2023-05-09 | 2024-11-12 | 重庆派金生物科技有限公司 | 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐 |
| WO2025072636A1 (en) * | 2023-09-28 | 2025-04-03 | Aperiam Bio, Inc. | Degradation of toxin in vivo |
| US20250161466A1 (en) | 2023-11-17 | 2025-05-22 | Biomarin Pharmaceutical Inc. | Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| EP0167411B1 (en) | 1984-07-05 | 1991-01-09 | Mitsubishi Kasei Corporation | Microbiological preparation of l-phenylalanine |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5466781A (en) * | 1991-05-24 | 1995-11-14 | Chiron Therapeutics | Process for purifying bacterially produced M-CSF |
| JP2930723B2 (ja) | 1992-11-19 | 1999-08-03 | アンティキャンサー インコーポレーテド | 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用 |
| EP0692029B1 (en) | 1992-12-04 | 2007-05-09 | Me Medical Enzymes Ag | Genetically engineered glutaminase and its use in therapy |
| DK75593D0 (https=) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| DK0851925T3 (da) | 1995-09-21 | 2005-11-28 | Genentech Inc | Humane Væksthormonvarianter |
| CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| US6395299B1 (en) | 1999-02-12 | 2002-05-28 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
| US6596849B1 (en) | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| AU2001257032A1 (en) | 2000-04-14 | 2001-10-30 | University Of South Carolina Research Foundation | Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase |
| US6967097B2 (en) | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| AU2002259281A1 (en) | 2001-05-21 | 2002-12-03 | Nektar Therapeutics Al, Corporation | Antibodies specific for poly(ethylene glycol) |
| US6939941B2 (en) | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
| KR20040088538A (ko) | 2002-02-26 | 2004-10-16 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 유전 인자의 재조합 방법 |
| WO2004024125A1 (en) * | 2002-09-16 | 2004-03-25 | Wyeth | Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same |
| JP2006516095A (ja) | 2002-11-14 | 2006-06-22 | ザ スクリップス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形 |
| US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| ATE471340T1 (de) * | 2004-02-11 | 2010-07-15 | Amylin Pharmaceuticals Inc | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
| WO2006034373A2 (en) | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| EP2886658A1 (en) | 2005-03-10 | 2015-06-24 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US20090011400A1 (en) | 2006-12-01 | 2009-01-08 | The Salk Institute for Biological Studies and The Regents of the University of California | Substrate switched ammonia lyases and mutases |
| US7560263B2 (en) * | 2007-08-17 | 2009-07-14 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| ES2690542T3 (es) | 2010-02-04 | 2018-11-21 | Biomarin Pharmaceutical Inc. | Método para purificar variantes de fenilalanina amoníaco-liasa procariotas |
-
2011
- 2011-02-03 ES ES15202466T patent/ES2690542T3/es active Active
- 2011-02-03 WO PCT/US2011/023534 patent/WO2011097335A2/en not_active Ceased
- 2011-02-03 EP EP11740323.8A patent/EP2531209B1/en active Active
- 2011-02-03 DK DK15202466.7T patent/DK3025728T3/en active
- 2011-02-03 JP JP2012552071A patent/JP5828844B2/ja active Active
- 2011-02-03 PT PT15202466T patent/PT3025728T/pt unknown
- 2011-02-03 EP EP18187522.0A patent/EP3479842A3/en not_active Withdrawn
- 2011-02-03 AU AU2011212929A patent/AU2011212929B2/en active Active
- 2011-02-03 PL PL15202466T patent/PL3025728T3/pl unknown
- 2011-02-03 SI SI201131589T patent/SI3025728T1/sl unknown
- 2011-02-03 CN CN201710117140.0A patent/CN106834261B/zh active Active
- 2011-02-03 CN CN2011800090746A patent/CN102753566A/zh active Pending
- 2011-02-03 HU HUE15202466A patent/HUE039516T2/hu unknown
- 2011-02-03 US US13/576,625 patent/US20130039898A1/en not_active Abandoned
- 2011-02-03 ES ES11740323.8T patent/ES2582459T3/es active Active
- 2011-02-03 LT LTEP15202466.7T patent/LT3025728T/lt unknown
- 2011-02-03 EP EP15202466.7A patent/EP3025728B1/en active Active
- 2011-02-03 EP EP22158491.5A patent/EP4062928A3/en active Pending
- 2011-02-03 CA CA2782444A patent/CA2782444C/en active Active
-
2012
- 2012-07-24 IL IL221099A patent/IL221099B/en active IP Right Grant
-
2016
- 2016-04-15 US US15/130,694 patent/US10221408B2/en active Active
- 2016-11-30 HK HK16113671.1A patent/HK1225299B/en unknown
-
2018
- 2018-02-08 IL IL257437A patent/IL257437B/en active IP Right Grant
- 2018-10-04 HR HRP20181602TT patent/HRP20181602T1/hr unknown
- 2018-10-17 CY CY181101068T patent/CY1120768T1/el unknown
-
2019
- 2019-01-11 US US16/246,300 patent/US11505790B2/en active Active
-
2022
- 2022-10-19 US US18/047,824 patent/US20240035013A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518893A5 (https=) | ||
| US20180085391A1 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
| JP6925688B2 (ja) | 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン | |
| US9925277B2 (en) | Polynucleotide compositions containing amino acids | |
| ES2922760T3 (es) | Vacunas de virus respiratorios | |
| US10023626B2 (en) | Polynucleotides encoding immune modulating polypeptides | |
| US20160194625A1 (en) | Chimeric polynucleotides | |
| JP6847664B2 (ja) | Ｐ９７−ポリヌクレオチド複合体 | |
| HRP20151268T1 (hr) | Pripravci prokariotske fenilalanin amonijak liaze i postupci upotrebe navedenog pripravka | |
| ES2919552T3 (es) | Procedimientos de utilización de polinucleotidos codificadores de ligando ox40 | |
| JP2010536759A5 (https=) | ||
| EP4218787A2 (en) | Peptides for treating muscle atrophy | |
| Jiang et al. | Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum | |
| EA013008B1 (ru) | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с | |
| JP4232866B2 (ja) | 細胞障害抑制剤 | |
| US20240100152A1 (en) | Modified polynucleotides encoding the sars-cov-2 spike protein for safer designs of coronavirus vaccines | |
| US20250101061A1 (en) | Upregulation of ferritin heavy chain 1 expression | |
| JP6484839B2 (ja) | 新規ペプチド及びその用途 | |
| AU2021201356A1 (en) | Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders | |
| CN115776909A (zh) | 皮下端粒酶抑制剂组合物及其使用方法 | |
| US10517928B2 (en) | Pharmaceutical composition for treating and/or preventing esophageal stenosis | |
| HK40090280A (zh) | 皮下端粒酶抑制剂组合物及其使用方法 | |
| O'Brien | OP28 Novel agents for ALL | |
| MXPA06007734A (es) | Agente preventivo para carcinogenesis de cancer de higado que contiene un compuesto basado en quinona como ingrediente activo. |